{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lazarus R"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["2277-2287"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8585490"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["398(10318)"],"pubmed_abstract":["<h4>Background</h4>Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.<h4>Methods</h4>In this multicentre, randomised, controlled, phase 4 trial, adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned (1:1) to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine. 3 weeks later the group who received placebo received the influenza vaccine, and vice versa. Participants were followed up for 6 weeks. The influenza vaccines were three seasonal, inactivated vaccines (trivalent, M"],"journal":["Lancet (London, England)"],"pubmed_title":["Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial."],"pmcid":["PMC8585490"],"funding_grant_id":["NIHR203243"],"pubmed_authors":["Haynes M","Nguyen-Van-Tam JS","Oliver C","Oliver E","Bradburn K","Feltham S","Leach R","Williams J","Rampling T","Burge S","Williams G","Harrhy S","Joyce K","Alaee S","Ricamara M","Talbot H","Manning N","Coleman T","Halliday A","Paterson J","Gardiner S","Owen D","Moran E","Broad L","Hutton D","Townley G","Close A","Finn A","Davies R","McLaughlin M","Hazell M","Davies L","Farrow A","Frayling S","Davies K","Silva L","Carmichael D","Ryan J","Pearce L","Clark T","Davies C","Rice D","Hewson J","Bray JJH","Driver K","Lloyd A","Nyland K","Pegler S","Faulkner B","Stringer R","Thomas A","Bowles J","David Otter A","Turkentine K","Cowley C","Haxton L","Nicholls L","Awal T","Bird S","Ekblad C","Smith RM","Price Z","Turner K","Cappel-Porter H","Bressington C","D'Agostino A","Allum E","Pynsent WB","Thirard R","Cross E","Tyler J","Hallis B","Shankland S","Barnett L","Taylor SL","Kellett Wright J","Hamal S","Adams K","Youlden N","Todd R","Garstang J","Anthony S","Beard C","Williams RL","Seneviratne M","Bishop S","Ramos L","Yim YTN","Kirby A","Carson-Stevens A","Higgins T","Regan K","Hicks B","Warnes B","Price E","Ford J","Rogers CA","Langton H","Mills B","Eglinton C","Ashton K","Brydon-Hill R","McCullagh L","Barratt A","Bodalia P","ComfluCOV Trial Group","Evans M","Sakagami Y","Lazarus R","Hill M","Goodwin J","Walton M","Kaminski R","Bisset J","Evans T","Figueirido S","Trembath L","Rea D","Ugoji J","McFadzean IJ","Smart K","Evans I","Iqbal A","Middleditch A","Lamb J","Hitchings B","Jones N","Wale K","Libri V","Baum H","Seaman S","Jones L","Knibbs L","Gooch KE","Tilzey G","Naik G","Whittley S","Santoloce S","Hills A","Iftikhar H","Kidd S","Phillipson A","Tucker D","F Mujadidi Y","Hembrough T","Cranfield C","Norman C","Rich M","Salem A","Clout M","Snape MD","Emmett SR","Bowyer C","Brimfield M","Walker-Smith T","Hua C","Baos S","McQueen A","Williamson K","Ryan KA","Salter-Hewitt J","Jacobsen N","Roots M","Riaz T","Hilton Z","Culliford L","Marriott A","Barron C","Bennett L","Northcott K","Smith J","D'Arcangelo S","Harris RA","Brown P","Samuels M","Gbadamoshi L","Harris A","Foxwell D","Eldridge E","Lewis-Clarke P","Maclean K","Oliver J","Chohan G","Aley PK","Tarling T"],"additional_accession":[]},"is_claimable":false,"name":"Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.","description":"<h4>Background</h4>Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.<h4>Methods</h4>In this multicentre, randomised, controlled, phase 4 trial, adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned (1:1) to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine. 3 weeks later the group who received placebo received the influenza vaccine, and vice versa. Participants were followed up for 6 weeks. The influenza vaccines were three seasonal, inactivated vaccines (trivalent, M","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-05-08T08:49:55.606Z","creation":"2022-02-11T14:57:18.581Z"},"accession":"S-EPMC8585490","cross_references":{"pubmed":["34774197"],"doi":["10.1016/S0140-6736(21)02329-1"]}}